Monoclonal antibodyPhase 3 trialInvestigational
Ramucirumab
How it works
Blocks vascular endothelial growth factor receptor 2 (VEGFR2), a protein involved in angiogenesis.
Cancer types
Efficacy
In clinical trials, ramucirumab improved overall survival in patients with metastatic colorectal cancer who have failed prior therapies.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Lorlatinib and Ramucirumab in Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Nivolumab and Ramucirumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| New Study Examines Effectiveness of Docetaxel Plus Ramucirumab After Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 33.3% (90% CI, 19.9-49.1), and the disease control rate was 90.9% (90% CI, 78.1-97.5). | Source → |
| Study Examines Effectiveness of Docetaxel and Ramucirumab for Lung Cancer Symptoms | Lung Cancer | observational | The pleural effusion control rate was 87%, and the cerebral edema control rate was 26%. | Source → |
| Testing Ramucirumab Plus Pembrolizumab for Stage IV Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise for Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 35.6 months, resulting in 77.8% at a 2-year survival rate. | Source → |
| Ramucirumab May Help Patients with Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Previous Cancer Treatment May Affect Neutropenia Risk in Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Ramucirumab plus docetaxel for lung cancer after immunotherapy | Lung Cancer | review | The pooled weighted median progression-free survival was 5.7 months, and the median overall survival was 11.2 months in the RAM + DTX ICI pre-treated group. | Source → |
| Different Response to Cancer Treatment in Two Types of Tumors | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.